Facilitators and barriers of Hepatitis B screening and vaccination

Vaccine. 2020 Jul 22;38(34):5447-5453. doi: 10.1016/j.vaccine.2020.06.045. Epub 2020 Jun 29.

Abstract

Background: Hepatitis B virus (HBV) infection is the most common cause of liver disease and liver cancer in Singapore, being endemic despite availability of an efficacious vaccine.

Objective: To assess the factors associated with HBV screening and vaccination.

Methods: Using mixed methods analysis, focus group discussions were conducted alongside a cross-sectional study amongst 784 Singapore Citizens and Permanent Residents aged 25-69 residing in Housing and Development Board (HDB) flats.

Results: Amongst the respondents, 50.6% were screened and 37.8% were vaccinated. The self-reported prevalence of HBV infection was 3.4% and that of HBsAg seropositivity among those screened was 4.3%. Routine health screening was the most common reason cited for screening (32.9%) while doctors' recommendation was the most common reason for vaccination (42.7%). For both screening and vaccination, knowledge and cost were the top facilitators and barriers respectively. Multivariable regression models revealed the most significant predictors for not undergoing screening to be poor knowledge (p < 0.001), the presence of stigma (p = 0.040) and not being employed in a healthcare sector (p = 0.022), while factors associated with not undergoing vaccination are that of having not undergone screening (p < 0.001) and the lack of importance placed on the knowledge of the possibility of HBV being a silent killer (p = 0.006).

Conclusion: Several facilitators and barriers are seen to regulate health-seeking behaviour towards HBV infection. Public initiatives including education and financial relief targeting specific population groups should be considered to increase the uptake of HBV screening and vaccination.

Keywords: Barriers; Facilitators; Hepatitis; Screening; Vaccination.

MeSH terms

  • Adult
  • Aged
  • Cross-Sectional Studies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines*
  • Hepatitis B virus
  • Hepatitis B* / diagnosis
  • Hepatitis B* / epidemiology
  • Hepatitis B* / prevention & control
  • Humans
  • Middle Aged
  • Singapore
  • Vaccination

Substances

  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines